Orion Oyj (ORINY) Stock Price & Analysis
Orion Oyj (ORINY) — price $48.79 (0.00%), as of the Oct 2, 2026 trading session; market cap $27.5B.
Educational signal · not a buy or sell recommendation · How to read this
Orion Oyj · ORINY · Healthcare · Drug Manufacturers - General
Orion Oyj is a Finnish pharmaceutical company specializing in the creation, production, and commercialization of medicines for both human and animal health, as well as the active components (APIs) essential for drug…
Price as of Oct 2, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $48.79 | |
| Change on the day | 0.00% | |
| 52-week range | $30.89–$48.79 | |
| Market capitalisation | $27.5B | |
| Price / earnings (trailing) | 19.38 | |
| Shares traded on the day | 5 | |
| Beta (volatility vs the S&P 500) | 0.29 | |
| Dividends per share (last 12 months) | $0.99 | |
| Dividend yield (last 12 months) | 2.03% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results
- · Earnings results
- · Earnings results
- · Earnings results
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Other perspectives
Council score for Orion Oyj (ORINY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 4, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the ORINY film — every key number, told as a short cinematic story
~2 min · open the film
What is Orion Oyj (ORINY), and what does it report?
Short answer · as of
Orion Oyj is a Finnish pharmaceutical company specializing in the creation, production, and commercialization of medicines for both human and animal health, as well as the active components (APIs) essential for drug… Healthcare / Drug Manufacturers General Headquarters: Orionintie 1A, Espoo, UU, 02200, FI. It employs 4,029 people and is led by Aino Anna Liisa Hurme. In Q2 FY2026 it reported revenue of $587M and net income of $158M. The market values it at $27.5B.
What do the latest results show for Orion Oyj (ORINY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $587M.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $596.23M Jul 17, 2026
- Latest report · revenue estimate
- $506.49M Jul 17, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 17, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 17, 2026 | $596.23M | $506.49M | $0.5800 | Not available |
| Apr 23, 2026 | $480.77M | $425.15M | $0.3700 | Not available |
| Feb 4, 2026 | $816.69M | $706.33M | $1.0800 | Not available |
| Oct 28, 2025 | Not available | Not available | $0.4000 | Not available |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $587M | $158M | $0.28 (diluted) |
| Q1 FY2026 | $470M | $102M | $0.18 (diluted) |
| Q4 FY2025 | $783M | $293M | $0.52 (diluted) |
| Q3 FY2025 | $475M | $108M | $0.19 (diluted) |
What are the financial strengths and risks for Orion Oyj (ORINY)?
Short answer
The distress and quality screens read Altman Z 27.92 · Piotroski F 7. Trailing ratios: ROE 50.0% · ROA 31.3% · current ratio 2.64 · earnings yield 5.1% · free-cash-flow yield 3.4%.
What has been published about Orion Oyj (ORINY)?
Orion Oyj Healthcare Stock: Key Questions Answered
These answers are editorial: 1 of these 8 answers is drawn from the ORINY research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is ORINY a good stock to buy?
Stock Expert AI does not rate ORINY buy, sell or hold. Orion Oyj has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ORINY stock price today?
The last price recorded on this page for Orion Oyj (ORINY) is $48.79, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
How does Orion Oyj ensure product innovation and development?
Orion Oyj ensures product innovation and development through a combination of in-house research and strategic external collaborations. The company invests in its own R&D capabilities to advance its human and veterinary pharmaceutical pipelines.
What are the key factors to evaluate for ORINY?
Evaluate ORINY on fundamentals, analyst consensus, and risk factors. P/E: 19.38x. **Expansion of Oncology Portfolio:** Orion Oyj's Nubeqa, for prostate cancer, represents a significant growth driver. Not financial advice.
How frequently does ORINY data refresh on this page?
ORINY's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ORINY's recent stock price performance?
Orion Oyj (ORINY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio spanning human prescription, self-care, and veterinary pharmaceuticals, reducing revenue concentration risk. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ORINY overvalued or undervalued right now?
Orion Oyj (ORINY) trades at 19.38x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ORINY before investing?
Before investing in Orion Oyj (ORINY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (31 figures)
The 31 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 26 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $48.79 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T09:34:24.494Z. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalization | $27.5B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-02. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
id.business_summary | Business description (FMP excerpt) | Orion Oyj is a Finnish pharmaceutical company specializing in the creation, production, and commercialization of medicines for both human and animal health, as well as the active components (APIs) essential for drug… | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.range52 | 52-week range | $30.89–$48.79 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 19.38 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 5 | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.29 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers General | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | Orionintie 1A, Espoo, UU, 02200, FI | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 4,029 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Aino Anna Liisa Hurme | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q2 FY2026 | $587M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $158M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-07-17.revenue_actual | Revenue · reported — report date 2026-07-17 | $596.23M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-17.revenue_estimated | Revenue · estimate — report date 2026-07-17 | $506.49M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-17.eps_actual | EPS · reported — report date 2026-07-17 | $0.5800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-23.revenue_actual | Revenue · reported — report date 2026-04-23 | $480.77M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-23.revenue_estimated | Revenue · estimate — report date 2026-04-23 | $425.15M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-23.eps_actual | EPS · reported — report date 2026-04-23 | $0.3700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-04.revenue_actual | Revenue · reported — report date 2026-02-04 | $816.69M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-04.revenue_estimated | Revenue · estimate — report date 2026-02-04 | $706.33M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-04.eps_actual | EPS · reported — report date 2026-02-04 | $1.0800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.eps_actual | EPS · reported — report date 2025-10-28 | $0.4000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.scores | Distress and quality screens | Altman Z 27.92 · Piotroski F 7 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 50.0% · ROA 31.3% · current ratio 2.64 · earnings yield 5.1% · free-cash-flow yield 3.4% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.99 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 2 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-03, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 2.03% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-07-17.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($596.23M) with the recorded estimate ($506.49M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
Fact-family notes
- Earnings-history note. Source series as of 2026-07-17. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-17.revenue_actual,earn.history.depth.2026-07-17.revenue_estimated,earn.history.depth.2026-07-17.revenue_actual.comparison,earn.history.depth.2026-07-17.eps_actual,earn.history.depth.2026-04-23.revenue_actual,earn.history.depth.2026-04-23.revenue_estimated,earn.history.depth.2026-04-23.eps_actual,earn.history.depth.2026-02-04.revenue_actual,earn.history.depth.2026-02-04.revenue_estimated,earn.history.depth.2026-02-04.eps_actual,earn.history.depth.2025-10-28.eps_actual.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.